Geron (NASDAQ:GERN) PT Raised to $6.00

Geron (NASDAQ:GERNGet Rating) had its price target boosted by Wedbush from $5.00 to $6.00 in a report issued on Wednesday, The Fly reports. Wedbush currently has an outperform rating on the biopharmaceutical company’s stock.

Separately, StockNews.com raised shares of Geron to a sell rating in a report on Tuesday, December 27th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $5.00.

Geron Price Performance

NASDAQ:GERN opened at $3.19 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.68 and a quick ratio of 2.68. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -8.86 and a beta of 0.76. The company has a 50 day moving average price of $2.25 and a 200-day moving average price of $2.19. Geron has a 1-year low of $0.99 and a 1-year high of $3.84.

Geron (NASDAQ:GERNGet Rating) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.12 million. Geron had a negative net margin of 8,563.80% and a negative return on equity of 110.76%. Equities research analysts forecast that Geron will post -0.38 EPS for the current year.

Institutional Investors Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in GERN. OmniStar Financial Group Inc. acquired a new stake in Geron in the 3rd quarter valued at $25,000. Merit Financial Group LLC acquired a new stake in Geron in the 2nd quarter valued at $27,000. Elmwood Wealth Management Inc. grew its stake in Geron by 44.6% in the 2nd quarter. Elmwood Wealth Management Inc. now owns 19,450 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 6,000 shares during the period. Lido Advisors LLC acquired a new stake in Geron during the 3rd quarter worth $35,000. Finally, High Net Worth Advisory Group LLC acquired a new stake in Geron during the 1st quarter worth $35,000. Institutional investors and hedge funds own 49.75% of the company’s stock.

About Geron

(Get Rating)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Read More

The Fly logo

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.